Press Releases Pre-2017

View current press releases

2018

Allegro Ophthalmics Prepares To Take Lead Compound Risuteganib To Phase 3, Appoints New CEO
August 21, 2018

2017

Allegro Ophthalmics Announces Positive Topline Results From DEL MAR Phase 2b Stage 2 Trial Evaluating Luminate® In Patients With Diabetic Macular Edema
August 09, 2017

Allegro Ophthalmics Secures $10.7 Million In Private Financing
July 24, 2017

Allegro Ophthalmics Names Melvin Sarayba, MD, Vice President Of Clinical Affairs
March 07, 2017

2016

Allegro Ophthalmics Completes Enrollment In DEL MAR Phase 2b, Stage 2 Clinical Trial Of Luminate® For The Treatment Of Diabetic Macular Edema
December 15, 2016

December 15, 2016 William J. Link, PhD, Joins Allegro Ophthalmics’ Board Of Directors
November 21, 2016

Allegro Ophthalmics Announces Positive Topline Results From DEL MAR Phase 2b Trial Evaluating Luminate® In Patients With Diabetic Macular Edema
October 13, 2016

Allegro Ophthalmics Announces Last Patient Enrolled In PACIFIC Phase 2b Clinical Trial Of Luminate® For Non-Proliferative Diabetic Retinopathy
October 03, 2016

Ron Kurtz, MD, And Mark Livingston Join Allegro Ophthalmics’ Board Of Directors
August 01, 2016

Allegro Ophthalmics Announces Two Executive Promotions
March 15, 2016

Allegro Ophthalmics Announces Last Patient Enrolled In Del Mar Phase 2b Clinical Trial Of Luminate ® For The Treatment Of Diabetic Macular Edema
January 05, 2016